Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer

Jeffrey A. Allen, Ashish Adlakha, Peter R. Bergethon

Research output: Contribution to journalArticlepeer-review

118 Scopus citations

Abstract

Objective: To describe a patient with reversible posterior leukoencephalopathy syndrome following the administration of bevacizumab (Avastin), a monoclonal antibody against vascular endothelial growth factor. Design: Case report/literature review. Setting: University hospital. Patient: A 52-year-old man receiving chemotherapy for stage IV rectal carcinoma. Results: Clinical and radiographic evidence consistent with reversible posterior leukoencephalopathy syndrome was found following the administration of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy and bevacizumab. Conclusions: Reversible posterior leukoencephalopathy syndrome following treatment with angiogenesis modulators can occur. In addition to raising clinical suspicion in appropriate patients, this report may yield clues to the pathophysiologic underpinnings of reversible posterior leukoencephalopathy syndrome.

Original languageEnglish (US)
Pages (from-to)1475-1478
Number of pages4
JournalArchives of Neurology
Volume63
Issue number10
DOIs
StatePublished - 2006

Fingerprint Dive into the research topics of 'Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer'. Together they form a unique fingerprint.

Cite this